ibusinesslines.com May 24, 2018

Arena Pharmaceuticals, Inc. (ARNA) has a Market value of 415.84 Million

19 June 2017, 05:56 | Jodi Jackson

Market Capitalization if basically the market value of the company's shares outstanding. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Arena Pharmaceuticals earned a coverage optimism score of 0.20 on Alpha One's scale. Wellington Grp Ltd Liability Partnership invested in 23.04M shares or 0.01% of the stock. The company had revenue of $6.60 million during the quarter, compared to analysts' expectations of $4.84 million.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Arena Pharmaceutical (NASDAQ:ARNA) high price target of $5 and with a conservative view have low price target of $2. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -5.76% where SMA50 and SMA200 are -5.43% and -15.15% respectively. This represents a change from most recent open price of 0.21%. Senzar Asset owns 1.88 million shares.

Arena Pharmaceuticals (NASDAQ:ARNA) last released its quarterly earnings results on Tuesday, May 9th. The company reported the earnings of $-0.09/Share in the last quarter where the estimated EPS by analysts was $-0.07/share.

Arena Pharmaceuticals, Inc. (ARNA) revenue totaled $8.07 million down -90.55% from the previous quarter. Arena Pharmaceuticals had a negative return on equity of 265.98% and a negative net margin of 339.63%. Analysts are expecting EPS growth rates to be at 79.40% this quarter and EPS estimate for next year reflect -2.90% growth rate. Cantor Fitzgerald analyst W. Tanner anticipates that the biopharmaceutical company will post earnings per share of ($0.27) for the year. If you are viewing this story on another publication, it was stolen and republished in violation of US & worldwide trademark and copyright law. If you are reading this article on another site, it was stolen and reposted in violation of USA and worldwide trademark and copyright legislation.

A number of other equities research analysts also recently issued reports on the stock.

ILLEGAL ACTIVITY NOTICE: "Leerink Swann Initiates Coverage on Arena Pharmaceuticals, Inc". The 200 SMA is considered so critically important a trend indicator that the event of the 50-day SMA crossing to the downside of the 200-day SMA is referred to as a death cross, signaling a serious bear market in a stock, index or other investment. The stock now has a consensus rating of "Buy" and an average price target of $5.50. The lowest 12-month price target for the shares is $2.00, which would be an increase of about 59% of its current value.

Zacks offers analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. The rating was maintained by WallachBeth Capital on Wednesday, October 28 with "Buy". The stock presently has a consensus rating of "Buy" and an average price target of $38.00.

A number of large investors have recently added to or reduced their stakes in ARNA. Credit Suisse AG now owns 395,948 shares of the biopharmaceutical company's stock valued at $577,000 after buying an additional 103,167 shares during the period.

In other Arena Pharmaceuticals news, insider Amit Munshi bought 50,000 shares of the business's stock in a transaction dated Wednesday, April 26th. Metropolitan Life Insurance Co. NY now owns 172,165 shares of the biopharmaceutical company's stock valued at $251,000 after buying an additional 17,565 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Arena Pharmaceuticals by 102.0% in the first quarter. Bank of America Corp DE now owns 96,379 shares of the biopharmaceutical company's stock valued at $141,000 after buying an additional 48,667 shares in the last quarter.

Arena Pharmaceuticals, Inc. (ARNA) traded with the volume of 5.45 Million shares while its average 3 months volume is at 2410 shares.

Stock research firms now have a positive stance on shares of Keysight Technologies, Inc. Arena Pharmaceuticals, Inc. (ARNA) has made its way to a 12-month decline of -30.69%. The Firm is focused on developing small molecule drugs across a range of therapeutic areas.

Other News

Trending Now

What we know about the London mosque attacker
Mr Basu thanked members of the public who detained the driver, saying "their restraint in the circumstances was commendable". No other suspects have been identified and police are investigating the incident under the Counter Terrorism Command.

Father's Day: Father a synonym for sacrifice!!
In this essay, Julie Hubschman talks about how losing her father has affected the way she views, and celebrates, Father's Day . Thomas said reflecting about his dad always helps him plan on how he can one day be a good dad, as well.

London Mayor Sadiq Khan: Dated UK tower blocks could be torn down
The prime minister insisted the government was doing everything possible to help those caught up in the tragedy. The first victim has been formally identified as 23-year-old Syrian refugee Mohammed Alhajali.

Theresa May condemns latest 'sickening' United Kingdom terror attack
Khalid said three of his friends were injured in the attack, including one who was hit and pinned under the van. Meanwhile, mayor of London Sadiq Khan pleaded for calmness, urging people to remain vigilant.

Jose Fonte at Confederations Cup #1
Nani's 21st minute goal was disallowed by video assistants because a Portugal player was offside in the build up to the goal . Earlier, Javier Hernandez became Mexico's record goal scorer when he cancelled out Ricardo Quaresma's early strike.

HUDSON'S BAY CO (HBAYF) Stock Rating Reaffirmed by Royal Bank Of Canada
CIBC reduced their target price on shares of Hudson's Bay Co from C$13.00 to C$10.50 in a report on Monday, June 12th. Royal Bank Of Canada now has a C$9.00 price target on the stock, down from their previous price target of C$13.00.

79 now believed to have died in London high-rise fire
The fire at the 24-story building has led to community anger and protests over the British government's response. Investigators are now trying to establish the cause of the fire and how it spread so quickly through the block.